LinkedIn
WebsiteIntroduction
GT Biopharma Inc (NASDAQ: GTBP) is a clinical-stage biopharmaceutical company headquartered in Brisbane, California. The company employs a proprietary natural killer (NK) cell engager platform, known as TriKE, to develop immuno-oncology therapies targeting hematologic malignancies such as acute lymphocytic leukemia, non-Hodgkin’s lymphoma, and acute myeloid leukemia, as well as multiple solid tumors.
Corporate Structure and Leadership
With a workforce of fewer than ten employees, GT Biopharma maintains a streamlined corporate structure. Executive leadership includes Michael Breen, Executive Chairman and Chief Executive Officer, who is an English-qualified solicitor with prior roles at BNP Paribas and Clyde & Co.; Jeffrey S. Miller, M.D., Consulting Senior Medical Director and Professor of Medicine at the University of Minnesota; and Alan L. Urban, Chief Financial Officer, a CPA with over 30 years of finance experience. The board of directors is chaired by Mr. Breen and comprises independent members Charles J. Casamento, Hilary Kramer, and David C. Mun-Gavin, each contributing extensive experience in biotechnology, finance, and corporate governance.
Biopharmaceuticals by little plant
Developments and News
On October 8, 2025, GT Biopharma’s share price closed at $1.0801, reflecting a 43.69% increase from the prior trading day, with volume reaching 10,569,324 shares—significantly above the three-month average of 344,642. According to Yahoo Finance, the 52-week low and high for the stock stand at $0.55 and $4.10, respectively. An analyst consensus one-year target of $11.00 has been reported as unchanged since August 2025.
Updates regarding the clinical pipeline are forthcoming, with potential data readouts anticipated in connection with ongoing trials for acute myeloid leukemia and other indications.
Financial and Strategic Analysis
As of October 8, 2025:
- Market capitalization: $2.696 million
- Total cash (most recent quarter): $5.23 million
- Net loss (trailing twelve months): $9.48 million
- Return on assets (trailing twelve months): -82.45%
- Return on equity (trailing twelve months): -181.98%
- Price/Book (most recent quarter): 0.79
- Beta (5-year monthly): 1.32
The company reports no debt. The negative earnings per share (-3.98 TTM) indicate ongoing investments in research and development. Strategically, GT Biopharma’s TriKE platform aims to differentiate itself through targeted NK-cell activation, positioning itself in early-stage immuno-oncology markets alongside larger competitors pursuing CAR-T and checkpoint inhibitors.
Market Position and Industry Context
Operating within the biotechnology research sector, GT Biopharma focuses on NK-cell engagers. The company is situated in Silicon Valley’s life-science corridor and competes with clinical-stage firms developing cellular and antibody-based immunotherapies. Its small scale and limited commercial revenue contrast with larger-cap peers; however, the proprietary TriKE constructs may meet unmet needs in refractory hematologic cancers if clinical efficacy is demonstrated.
tl;dr
On October 8, 2025, GT Biopharma shares increased 43.69% to $1.0801 on a volume of 10.6 million. The company holds $5.23 million in cash against a net loss of $9.48 million (TTM) and zero debt. Upcoming catalysts include mid-August 2025 earnings and clinical data readouts for TriKE in acute myeloid leukemia. The consensus one-year target remains at $11.00.
